An Open, Randomised, Three Period Cross, Single Centre, Phase 1 Pharmacokinetic Interaction Study of the Reflux Inhibitor AZD3355 150 mg Bid and Esomeprazole 40 mg od After 7 Days of Treatment in Healthy Volunteers.

Trial Profile

An Open, Randomised, Three Period Cross, Single Centre, Phase 1 Pharmacokinetic Interaction Study of the Reflux Inhibitor AZD3355 150 mg Bid and Esomeprazole 40 mg od After 7 Days of Treatment in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Esomeprazole; Lesogaberan
  • Indications Gastro-oesophageal reflux
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2009 Results published as an abstract in the proceedings of the Digestive Disease Week 2009.
    • 17 Jun 2008 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top